Formulary Search Results for: CALCIUM AND VITAMIN D
2.3.2 Drugs for arrhythmias - View Category
Restrictions:
Restricted to patients for the prevention of recurrence of AF in patients in whom beta-blockers, class 1c drugs and amiodarone are contraindicated, ineffective or not tolerated and who do not have a diagnosis of heart failure.
2.3.2 Drugs for arrhythmias - View Category
2.5.4 Alpha-adrenoceptor blocking drugs - View Category
2.5.6 Other medicines beneficial in heart failure - View Category
Prescribing Notes:
Refer to the NHSGGC Heart Failure treatment guideline for advice on initiation and monitoring.
For use in Chronic Kidney Disease, see section 7.5
2.6.2 Calcium-channel blockers - View Category
Prescribing Notes:
Prescribe by brand name. Diltiazem should not be prescribed in conjunction with beta-blockers because of the risk of severe bradycardia.
2.6.4 Peripheral vasodilators and related drugs - View Category
Restrictions:
Use for the treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstruction syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy is restricted to specialist use.
2.7.1 Inotropic sympathomimetics - View Category
2.7.1 Inotropic sympathomimetics - View Category
2.8.1 Parenteral anticoagulants - View Category
2.8.2 Oral anticoagulants - View Category
Restrictions:
Restricted to use in accordance with the prescribing notes below
Prescribing Notes:
Prevention of stroke in atrial fibrillation
Use for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation and with one or more risk factors is restricted to:
- newly diagnosed patients
- those currently receiving warfarin who have poor INR control despite evidence that they are complying
- patients with allergy or intolerable side effects from coumarin anticoagulants
- patients for whom warfarin has been clinically excluded as a therapeutic option but anticoagulation is deemed safe and appropriate
Risk factors include:
- previous stroke, transient ischaemic attack, or systemic embolism
- left ventricular ejection fraction <40%
- symptomatic heart failure, ≥ New York Heart Association (NYHA) Class 2
- age ≥75 years
- age ≥65 years associated with one of the following: diabetes mellitus, coronary artery disease or hypertension
Further advice can be accessed via the NHSGGC Atrial Fibrillation guideline and the Prescribing Resources section of this website
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE
Use is restricted to patients who fail to tolerate other therapeutic options or where other agents are not appropriate, where the intended duration of treatment is 3-6 months. Where indefinite duration is indicated, the treatment of choice should be or apixaban or low molecular weight heparin followed by warfarin.
VTE prophylaxis in orthopaedic surgery
- The use for the primary prevention of venous thromboembolic events (VTE) in adults undergoing elective hip or knee replacement surgery is non-formulary.